Acylcarnitines in Human Heart Failure

What role do circulating acylcarnitines play in the heart failure metabolome? Listen as Guest Editor Sumanth Prabhu (University of Alabama at Birmingham) interviews lead author and Associate Editor Christine Des Rosiers (Universite de Montreal, Montreal Heart Institute), first author Matthieu Ruiz (Universite de Montreal, Montreal Heart Institute), and renowned content expert Heinrich Taegtmeyer (University of Texas Medical School), about the intriguing new study analyzing fatty acid metabolic perturbations in patients with heart failure with reduced ejection fraction (HFrEF). Des Rosiers and co-authors began their investigations over 10 years ago, and through persistence and new mass spectrometry analytical technologies, pursued a novel mechanism “contributing to the global lipid perturbation in human heart failure.” The work by Ruiz et al was published in the AJP-Heart and Circ Call for Papers on Heart Failure: Novel Therapeutic Pathways Emerging from Basic Science. This special extended podcast discusses the innovative techniques utilized by Des Rosiers, Ruiz and colleagues, along with the passion and tenacity required to understand the alterations in heart failure in long-chain fatty acid metabolism in heterogenous HFrEF patient cohorts. Did the authors find correlations to cardiac structural parameters, along with links between very long chain acylcarnitines and arrhythmias? Listen and learn.

 

Matthieu Ruiz, Francois Labarthe, Annik Fortier, Bertrand Bouchard, Julie Thompson Legault, Virginie Bolduc, Odile Rigal, Jane Chen, Anique Ducharme, Peter A Crawford, Jean-Claude Tardif, Christine Des Rosiers Circulating Acylcarnitine Profile in Human Heart Failure: A Surrogate of Fatty Acid Metabolic Dysregulation in Mitochondria and Beyond Am J Physiol Heart Circ Physiol, published July 14, 2017. DOI: 10.1152/ajpheart.00820.2016

00:0000:00
Share | Download(Loading)